Galmed Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub as well as an extended cash runway, it plans to broaden its drug development activities. The planned expansion consists of two additional programs over the next two years.

Galmed Pharmaceuticals Ltd是一家临床阶段的纤维炎症适应症生物制药公司，今天宣布，根据其第三阶段NASH研究开放标签部分最近公布的结果，关于SCD1作为关键代谢信号枢纽的作用的新科学出版物以及延长的现金跑道，它计划扩大其药物开发活动。。

One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.

。另一个项目旨在揭示新的作用机制，从而开发一种新型的基于Aramchol的药物组合，靶向心脏纤维化或心脏瘢痕形成，这种疾病发生在许多可能导致心脏功能障碍和衰竭的心血管疾病中。

The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.Recent scientific publications reveal that: Allen Baharaff, President and CEO of Galmed Pharmaceuticals commented: 'The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers.

该公司计划在2024年第四季度发布这些项目中体外和离体研究的新数据。最近的科学出版物显示：Galmed Pharmaceuticals总裁兼首席执行官艾伦·巴哈拉夫（Allen Baharaf）评论道：“Galmed计划在未来几年重点关注的条件是影响全球数百万人的主要公共卫生问题，并给卫生服务提供者带来巨大的经济负担。

SCD1 is a key enzyme that critically regulates many physiological processes, thereby promoting the progression of cardiovascular, cancer and neurodegenerative diseases. We are leveraging on two decades of development of the most clinically advanced SCD1 inhibitor (Aramchol) to date as we broaden our drug development activities.

SCD1是一种关键酶，可严格调节许多生理过程，从而促进心血管，癌症和神经退行性疾病的进展。随着我们扩大药物开发活动，我们正在利用迄今为止临床上最先进的SCD1抑制剂（Aramchol）的二十年开发。

Recent scientific breakthroughs identifying the role of SCD1 as a 'master-switch' in lipid m.

最近的科学突破确定了SCD1在脂质m中作为“主开关”的作用。